AIMS/HYPOTHESIS: We sought to evaluate if the cellular localisation and molecular species of diacylglycerol (DAG) were related to insulin sensitivity in human skeletal muscle. METHODS: Healthy sedentary obese controls (Ob; n = 6; mean±SEM age 39.5 ± 2.3 years; mean ± SEM BMI 33.3 ± 1.4 kg/m(2)), individuals with type 2 diabetes (T2D; n = 6; age 44 ± 1.8 years; BMI 30.1 ± 2.3 kg/m(2)), and lean endurance-trained athletes (Ath; n = 10; age 35.4 ± 3.1 years; BMI 23.3 ± 0.8 kg/m(2)) were studied. Insulin sensitivity was determined using an IVGTT. Muscle biopsy specimens were taken after an overnight fast, fractionated using ultracentrifugation, and DAG species measured using liquid chromatography/MS/MS. RESULTS: Total muscle DAG concentration was higher in the Ob (mean ± SEM 13.3 ± 1.0 pmol/μg protein) and T2D (15.2 ± 1.0 pmol/μg protein) groups than the Ath group (10.0 ± 0.78 pmol/μg protein, p = 0.002). The majority (76-86%) DAG was localised in the membrane fraction for all groups, but was lowest in the Ath group (Ob, 86.2 ± 0.98%; T2D, 84.2 ± 1.2%; Ath, 75.9 ± 2.7%; p = 0.008). There were no differences in cytoplasmic DAG species (p > 0.12). Membrane DAG species C18:0/C20:4, Di-C16:0 and Di-C18:0 were significantly more abundant in the T2D group. Cytosolic DAG species were negatively related to activation of protein kinase C (PKC)ε but not PKCθ, whereas membrane DAG species were positively related to activation of PKCε, but not PKCθ. Only total membrane DAG (r = -0.624, p = 0.003) and Di-C18:0 (r = -0.595, p = 0.004) correlated with insulin sensitivity. Disaturated DAG species were significantly lower in the Ath group (p = 0.001), and significantly related to insulin sensitivity (r = -0.642, p = 0.002). CONCLUSIONS/ INTERPRETATION: These data indicate that both cellular localisation and composition of DAG influence the relationship to insulin sensitivity. Our results suggest that only saturated DAG in skeletal muscle membranes are related to insulin resistance in humans.
AIMS/HYPOTHESIS: We sought to evaluate if the cellular localisation and molecular species of diacylglycerol (DAG) were related to insulin sensitivity in human skeletal muscle. METHODS: Healthy sedentary obese controls (Ob; n = 6; mean±SEM age 39.5 ± 2.3 years; mean ± SEM BMI 33.3 ± 1.4 kg/m(2)), individuals with type 2 diabetes (T2D; n = 6; age 44 ± 1.8 years; BMI 30.1 ± 2.3 kg/m(2)), and lean endurance-trained athletes (Ath; n = 10; age 35.4 ± 3.1 years; BMI 23.3 ± 0.8 kg/m(2)) were studied. Insulin sensitivity was determined using an IVGTT. Muscle biopsy specimens were taken after an overnight fast, fractionated using ultracentrifugation, and DAG species measured using liquid chromatography/MS/MS. RESULTS: Total muscle DAG concentration was higher in the Ob (mean ± SEM 13.3 ± 1.0 pmol/μg protein) and T2D (15.2 ± 1.0 pmol/μg protein) groups than the Ath group (10.0 ± 0.78 pmol/μg protein, p = 0.002). The majority (76-86%) DAG was localised in the membrane fraction for all groups, but was lowest in the Ath group (Ob, 86.2 ± 0.98%; T2D, 84.2 ± 1.2%; Ath, 75.9 ± 2.7%; p = 0.008). There were no differences in cytoplasmic DAG species (p > 0.12). Membrane DAG species C18:0/C20:4, Di-C16:0 and Di-C18:0 were significantly more abundant in the T2D group. Cytosolic DAG species were negatively related to activation of protein kinase C (PKC)ε but not PKCθ, whereas membrane DAG species were positively related to activation of PKCε, but not PKCθ. Only total membrane DAG (r = -0.624, p = 0.003) and Di-C18:0 (r = -0.595, p = 0.004) correlated with insulin sensitivity. Disaturated DAG species were significantly lower in the Ath group (p = 0.001), and significantly related to insulin sensitivity (r = -0.642, p = 0.002). CONCLUSIONS/ INTERPRETATION: These data indicate that both cellular localisation and composition of DAG influence the relationship to insulin sensitivity. Our results suggest that only saturatedDAG in skeletal muscle membranes are related to insulin resistance in humans.
Authors: M E Griffin; M J Marcucci; G W Cline; K Bell; N Barucci; D Lee; L J Goodyear; E W Kraegen; M F White; G I Shulman Journal: Diabetes Date: 1999-06 Impact factor: 9.461
Authors: C Schmitz-Peiffer; C L Browne; N D Oakes; A Watkinson; D J Chisholm; E W Kraegen; T J Biden Journal: Diabetes Date: 1997-02 Impact factor: 9.461
Authors: A Avignon; K Yamada; X Zhou; B Spencer; O Cardona; S Saba-Siddique; L Galloway; M L Standaert; R V Farese Journal: Diabetes Date: 1996-10 Impact factor: 9.461
Authors: Jason K Kim; Jonathan J Fillmore; Mary Jean Sunshine; Bjoern Albrecht; Takamasa Higashimori; Dong-Wook Kim; Zhen-Xiang Liu; Timothy J Soos; Gary W Cline; William R O'Brien; Dan R Littman; Gerald I Shulman Journal: J Clin Invest Date: 2004-09 Impact factor: 14.808
Authors: S O Shepherd; M Cocks; P J Meikle; N A Mellett; A M Ranasinghe; T A Barker; A J M Wagenmakers; C S Shaw Journal: Int J Obes (Lond) Date: 2017-07-24 Impact factor: 5.095
Authors: Benjamin J Ryan; Michael W Schleh; Cheehoon Ahn; Alison C Ludzki; Jenna B Gillen; Pallavi Varshney; Douglas W Van Pelt; Lisa M Pitchford; Thomas L Chenevert; Rachel A Gioscia-Ryan; Suzette M Howton; Thomas Rode; Scott L Hummel; Charles F Burant; Jonathan P Little; Jeffrey F Horowitz Journal: J Clin Endocrinol Metab Date: 2020-08-01 Impact factor: 5.958
Authors: Paul T Reidy; Alec I McKenzie; Ziad Mahmassani; Vincent R Morrow; Nikol M Yonemura; Paul N Hopkins; Robin L Marcus; Matthew T Rondina; Yu Kuei Lin; Micah J Drummond Journal: J Physiol Date: 2018-10-09 Impact factor: 5.182
Authors: Lisa S Chow; Douglas G Mashek; Erin Austin; Lynn E Eberly; Xuan-Mai Persson; Mara T Mashek; Elizabeth R Seaquist; Michael D Jensen Journal: Am J Physiol Endocrinol Metab Date: 2014-05-20 Impact factor: 4.310
Authors: Leigh Perreault; Anne P Starling; Deborah Glueck; Joseph T Brozinick; Phil Sanders; Parker Siddall; Ming Shang Kuo; Dana Dabelea; Bryan C Bergman Journal: J Clin Endocrinol Metab Date: 2015-11-17 Impact factor: 5.958